IL218084A - Compounds and preparations as protein kinase inhibitors - Google Patents
Compounds and preparations as protein kinase inhibitorsInfo
- Publication number
- IL218084A IL218084A IL218084A IL21808412A IL218084A IL 218084 A IL218084 A IL 218084A IL 218084 A IL218084 A IL 218084A IL 21808412 A IL21808412 A IL 21808412A IL 218084 A IL218084 A IL 218084A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- compounds
- protein kinase
- kinase inhibitors
- inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23807309P | 2009-08-28 | 2009-08-28 | |
| US31303910P | 2010-03-11 | 2010-03-11 | |
| PCT/US2010/046930 WO2011025927A1 (en) | 2009-08-28 | 2010-08-27 | Compounds and compositions as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL218084A0 IL218084A0 (en) | 2012-04-30 |
| IL218084A true IL218084A (en) | 2016-11-30 |
Family
ID=42782253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218084A IL218084A (en) | 2009-08-28 | 2012-02-13 | Compounds and preparations as protein kinase inhibitors |
Country Status (49)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| RU2571930C2 (ru) | 2010-02-25 | 2015-12-27 | Дана-Фарбер Кэнсер Инститьют, Инк. | Мутации braf, обеспечивающие резистентность к ингибиторам braf |
| US8907270B2 (en) | 2010-06-30 | 2014-12-09 | Schlumberger Technology Corporation | Method and apparatus for gain regulation in a gamma detector |
| CN108542906A (zh) * | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| SI2782557T1 (sl) | 2011-11-23 | 2019-02-28 | Array Biopharma, Inc., | Farmacevtske formulacije |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| JP2015503505A (ja) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリールおよびその使用 |
| BR112014023496A2 (pt) | 2012-03-28 | 2017-07-18 | Dana Farber Cancer Inst Inc | mutantes c-raf que conferem resistência a inibidores de raf |
| CA2878469A1 (en) | 2012-07-18 | 2014-01-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| TR201904980T4 (tr) | 2012-08-07 | 2019-05-21 | Novartis Ag | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. |
| SG10201708494QA (en) | 2012-08-17 | 2017-11-29 | Hoffmann La Roche | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| WO2014047330A1 (en) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Novel raf kinase inhibitors |
| AU2013343425A1 (en) * | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| SI2976106T1 (sl) * | 2013-03-21 | 2021-08-31 | Array Biopharma Inc. | Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec |
| TWI634114B (zh) | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| CA2912568A1 (en) * | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| AU2014368906B2 (en) * | 2013-12-20 | 2020-04-30 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of ERK and RAF inhibitors |
| KR20160100975A (ko) * | 2013-12-23 | 2016-08-24 | 노파르티스 아게 | 제약 조합물 |
| US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| ME03489B (me) | 2014-01-31 | 2020-01-20 | Novartis Ag | Molekuli antitijela na tim-3 i njihove upotrebe |
| DE102015103158A1 (de) | 2014-03-04 | 2015-09-10 | Bergische Universität Wuppertal | Verbindungen für die Behandlung des Melanoms |
| JP6576962B2 (ja) | 2014-03-14 | 2019-09-18 | ノバルティス アーゲー | Ｌａｇ−３に対する抗体分子およびその使用 |
| WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| EP3143166A4 (en) | 2014-05-16 | 2018-04-18 | University of Massachusetts | Treating chronic myelogenous leukemia (cml) |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US10167279B2 (en) * | 2014-09-12 | 2019-01-01 | Novartis Ag | Compounds and compositions as RAF kinase inhibitors |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3268035A4 (en) | 2015-03-10 | 2018-10-31 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP3317301B1 (en) | 2015-07-29 | 2021-04-07 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
| HUE057837T2 (hu) | 2015-11-03 | 2022-06-28 | Janssen Biotech Inc | PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik |
| EP4424322A3 (en) | 2015-12-17 | 2025-04-16 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| RU2729518C2 (ru) | 2015-12-30 | 2020-08-07 | Сент-Луис Юниверсити | Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина |
| RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
| KR102439911B1 (ko) | 2016-06-03 | 2022-09-05 | 어레이 바이오파마 인크. | 제약학적 복합제제 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107540699A (zh) * | 2017-10-16 | 2018-01-05 | 康化（上海）新药研发有限公司 | 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法 |
| WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7262843B2 (ja) * | 2018-07-12 | 2023-04-24 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | ジアリールピラゾール化合物、該化合物を含む組成物およびその使用 |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
| CN113811303A (zh) | 2019-05-16 | 2021-12-17 | 伊莱利利公司 | 用于治疗brafv600e结直肠癌的erk1/2抑制剂与braf抑制剂和egfr抑制剂的三药组合 |
| KR20220131229A (ko) | 2019-12-05 | 2022-09-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도 |
| TWI837478B (zh) | 2020-06-09 | 2024-04-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| EP4196228A1 (en) | 2020-08-13 | 2023-06-21 | Albert Einstein College of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| AU2021358394A1 (en) | 2020-10-05 | 2023-04-13 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma |
| US20240310266A1 (en) | 2021-03-18 | 2024-09-19 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CA3222549A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| CN114557977A (zh) * | 2022-02-16 | 2022-05-31 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024163166A1 (en) * | 2023-01-30 | 2024-08-08 | 5Metis, Inc. | Boron containing compounds and their uses |
| CN120813358A (zh) | 2023-04-06 | 2025-10-17 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| CN116396222A (zh) * | 2023-04-10 | 2023-07-07 | 上海睿腾医药科技有限公司 | 一种康奈非尼中间体1-（3-氨基-1-异丙基-1h-吡唑-4-基）乙-1-酮的合成方法 |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104250A (en) * | 1976-08-11 | 1978-08-01 | Borg-Warner Corporation | Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents |
| JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
| DE3571974D1 (en) | 1984-12-06 | 1989-09-07 | Pfizer | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| EP0952770A4 (en) | 1995-09-07 | 1999-12-22 | Fuisz Technologies Ltd | SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| IL127210A0 (en) | 1996-05-23 | 1999-09-22 | Applied Research Systems | Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| IL132991A (en) | 1997-05-22 | 2005-11-20 | Searle & Co | Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| CA2396380C (en) | 1999-12-23 | 2015-04-21 | David Hayes | Improved pharmaceutical compositions for poorly soluble drugs |
| WO2002018654A1 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| HUP0600235A3 (en) | 2001-10-25 | 2008-04-28 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
| WO2003055860A1 (en) | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
| DK3000810T3 (en) | 2002-03-13 | 2017-10-16 | Array Biopharma Inc | N3-ALKYLED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR |
| AU2004273615B2 (en) | 2003-09-23 | 2009-01-15 | Novartis Ag | Combination of a VEGF receptor inhibitor with a chemotherapeutic agent |
| CA2545942C (en) | 2003-11-14 | 2012-07-10 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| KR20060127032A (ko) | 2004-01-09 | 2006-12-11 | 노파르티스 아게 | Ｉｇｆ―ｉｒ 억제제로서의페닐-[4-(3-페닐-1ｈ-피라졸-4-일)-피리미딘-2-일]-아민유도체 |
| AU2005254982B2 (en) | 2004-06-10 | 2008-11-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| KR20070113295A (ko) | 2005-03-17 | 2007-11-28 | 노파르티스 아게 | 티로신/트레오닌 키나제 억제제, 특히 ｂ-ｒａｆ 키나제억제제로서의ｎ-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4ｂ-트리아자플루오렌-9-일)-페닐]벤즈아미드 |
| US20070099856A1 (en) | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US20090214645A1 (en) | 2005-08-22 | 2009-08-27 | Andrea Kramer | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| EP1917258A2 (en) | 2005-08-26 | 2008-05-07 | SmithKline Beecham Corporation | Pyrimidinyl-pyrazole inhibitors of aurora kinases |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| CA2643066A1 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| JP2009532497A (ja) | 2006-04-05 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 癌を処置するための治療剤の組合せ |
| WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| CA2662937A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| KR20090074202A (ko) | 2006-09-18 | 2009-07-06 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｅｇｆｒ 돌연변이를 갖는 암을 치료하는 방법 |
| EP2057146A1 (en) | 2006-10-02 | 2009-05-13 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| KR20090063240A (ko) * | 2006-10-06 | 2009-06-17 | 아이알엠 엘엘씨 | 단백질 키나제 억제제 및 그의 사용 방법 |
| JP2010519209A (ja) | 2007-02-15 | 2010-06-03 | ノバルティス アーゲー | 癌を処置するためのｌｂｈ５８９と他の治療剤の組み合わせ剤 |
| US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| AU2008281543A1 (en) * | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as Raf inhibitors |
| BRPI0818340A2 (pt) | 2007-10-19 | 2015-04-22 | Abbott Gmbh & Co Kg | Produto de dispersão sólida de fármacos baseados em n-aril uréia |
| US8785486B2 (en) * | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| KR101408517B1 (ko) * | 2008-03-21 | 2014-06-17 | 노파르티스 아게 | 신규한 헤테로시클릭 화합물 및 그의 용도 |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| SI2324008T1 (sl) * | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoli kot protein-kinazni inhibitorji |
| NZ590747A (en) | 2008-07-28 | 2012-11-30 | Gilead Sciences Inc | Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds |
| EP2350052B1 (en) | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
| ME02640B (me) | 2008-10-07 | 2017-06-20 | Kudos Pharm Ltd | Farmaceutske formulacije 514 |
| WO2010056662A1 (en) * | 2008-11-11 | 2010-05-20 | University Of Washington | Activated wnt-beta-catenin signaling in melanoma |
| US8524707B2 (en) * | 2008-12-19 | 2013-09-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| AR075180A1 (es) | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| RU2402602C1 (ru) | 2009-02-12 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| TWI532484B (zh) | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| ES2679379T3 (es) * | 2009-06-15 | 2018-08-24 | Nerviano Medical Sciences S.R.L. | Derivados de pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| JP5806239B2 (ja) | 2010-01-27 | 2015-11-10 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾールのスルホンアミド誘導体 |
| RU2639876C2 (ru) | 2010-03-30 | 2017-12-25 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| EP2601185B1 (en) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| DK2688572T3 (en) | 2011-03-21 | 2017-06-12 | Valcuria Ab | PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF |
| ES2595407T3 (es) | 2011-06-14 | 2016-12-29 | Novartis Ag | Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa |
| CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| SI2782557T1 (sl) | 2011-11-23 | 2019-02-28 | Array Biopharma, Inc., | Farmacevtske formulacije |
| AU2013343425A1 (en) | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| US10576680B2 (en) | 2015-11-19 | 2020-03-03 | The Boeing Company | Modular thermoforming system |
-
2010
- 2010-08-26 JO JOP/2010/0297A patent/JO3002B1/ar active
- 2010-08-26 AR ARP100103123A patent/AR077975A1/es active IP Right Grant
- 2010-08-27 RS RS20170017A patent/RS55568B1/sr unknown
- 2010-08-27 SI SI201030711T patent/SI2470526T1/sl unknown
- 2010-08-27 EP EP10748211.9A patent/EP2470526B1/en active Active
- 2010-08-27 NZ NZ598924A patent/NZ598924A/xx unknown
- 2010-08-27 HU HUE14152945A patent/HUE032847T2/hu unknown
- 2010-08-27 PL PL14152945T patent/PL2727918T3/pl unknown
- 2010-08-27 ES ES14152945.3T patent/ES2610825T3/es active Active
- 2010-08-27 ES ES10748211.9T patent/ES2492499T3/es active Active
- 2010-08-27 PT PT141529453T patent/PT2727918T/pt unknown
- 2010-08-27 US US12/870,130 patent/US8501758B2/en not_active Ceased
- 2010-08-27 PE PE2012000268A patent/PE20120861A1/es active IP Right Grant
- 2010-08-27 MX MX2012002546A patent/MX2012002546A/es active IP Right Grant
- 2010-08-27 CN CN201410040923.XA patent/CN103896921B/zh active Active
- 2010-08-27 HR HRP20140799AT patent/HRP20140799T1/hr unknown
- 2010-08-27 LT LTEP14152945.3T patent/LT2727918T/lt unknown
- 2010-08-27 WO PCT/US2010/046930 patent/WO2011025927A1/en not_active Ceased
- 2010-08-27 UA UAA201203042A patent/UA112285C2/uk unknown
- 2010-08-27 BR BR112012004453-2A patent/BR112012004453B1/pt active IP Right Grant
- 2010-08-27 CN CN201080038197.8A patent/CN102725283B/zh active Active
- 2010-08-27 GE GEAP201012645A patent/GEP20146102B/en unknown
- 2010-08-27 AU AU2010286569A patent/AU2010286569C1/en active Active
- 2010-08-27 DK DK10748211.9T patent/DK2470526T3/da active
- 2010-08-27 EA EA201200373A patent/EA025222B1/ru not_active IP Right Cessation
- 2010-08-27 DK DK14152945.3T patent/DK2727918T3/da active
- 2010-08-27 RS RS20140430A patent/RS53489B1/sr unknown
- 2010-08-27 CA CA2771775A patent/CA2771775C/en active Active
- 2010-08-27 EA EA201500175A patent/EA201500175A1/ru unknown
- 2010-08-27 SM SM20170036T patent/SMT201700036T1/it unknown
- 2010-08-27 SI SI201031371A patent/SI2727918T1/sl unknown
- 2010-08-27 IN IN2469DEN2012 patent/IN2012DN02469A/en unknown
- 2010-08-27 CU CU2012000034A patent/CU24110B1/es active IP Right Grant
- 2010-08-27 PT PT107482119T patent/PT2470526E/pt unknown
- 2010-08-27 JP JP2012527014A patent/JP5475888B2/ja active Active
- 2010-08-27 PL PL10748211T patent/PL2470526T3/pl unknown
- 2010-08-27 SG SG10201405311TA patent/SG10201405311TA/en unknown
- 2010-08-27 MY MYPI2012000611A patent/MY156259A/en unknown
- 2010-08-27 UY UY0001032860A patent/UY32860A/es active IP Right Grant
- 2010-08-27 ME MEP-2014-94A patent/ME01860B/me unknown
- 2010-08-27 EP EP14152945.3A patent/EP2727918B1/en active Active
- 2010-08-27 KR KR1020127007860A patent/KR101413392B1/ko active Active
- 2010-08-27 SG SG2012009304A patent/SG178351A1/en unknown
- 2010-08-27 ME MEP-2017-6A patent/ME02684B/me unknown
-
2012
- 2012-02-09 CL CL2012000340A patent/CL2012000340A1/es unknown
- 2012-02-13 IL IL218084A patent/IL218084A/en active IP Right Grant
- 2012-02-17 TN TNP2012000081A patent/TN2012000081A1/en unknown
- 2012-02-24 DO DO2012000051A patent/DOP2012000051A/es unknown
- 2012-02-24 NI NI201200029A patent/NI201200029A/es unknown
- 2012-02-24 CO CO12032570A patent/CO6612222A2/es active IP Right Grant
- 2012-02-27 HN HN2012000441A patent/HN2012000441A/es unknown
- 2012-02-27 GT GT201200053A patent/GT201200053A/es unknown
- 2012-02-28 EC ECSP12011700 patent/ECSP12011700A/es unknown
- 2012-02-28 CR CR20120102A patent/CR20120102A/es unknown
- 2012-03-19 ZA ZA2012/02020A patent/ZA201202020B/en unknown
- 2012-03-23 MA MA34716A patent/MA33604B1/fr unknown
-
2013
- 2013-06-28 US US13/931,111 patent/US9314464B2/en active Active
-
2014
- 2014-02-06 JP JP2014021339A patent/JP6045519B2/ja active Active
- 2014-09-12 SM SM201400133T patent/SMT201400133B/xx unknown
-
2016
- 2016-01-13 US US14/994,710 patent/US9593099B2/en active Active
- 2016-01-13 US US14/994,827 patent/US9593100B2/en active Active
- 2016-03-15 US US15/070,905 patent/US10005761B2/en active Active
- 2016-06-10 US US15/179,644 patent/US9850230B2/en active Active
- 2016-06-10 US US15/179,385 patent/US9850229B2/en active Active
-
2017
- 2017-01-03 HR HRP20170005TT patent/HRP20170005T1/hr unknown
- 2017-01-10 CY CY20171100028T patent/CY1118452T1/el unknown
- 2017-01-19 SM SM201700036T patent/SMT201700036B/it unknown
- 2017-11-20 US US15/818,082 patent/US10576080B2/en active Active
- 2017-11-20 US US15/818,264 patent/US10568884B2/en active Active
-
2019
- 2019-02-12 LU LU00101C patent/LUC00101I2/fr unknown
- 2019-02-12 LU LU00102C patent/LUC00102I2/fr unknown
- 2019-03-01 HU HUS1900013C patent/HUS1900013I1/hu unknown
- 2019-03-01 HU HUS1900012C patent/HUS1900012I1/hu unknown
- 2019-03-05 NO NO2019012C patent/NO2019012I1/no unknown
- 2019-03-05 NO NO2019011C patent/NO2019011I1/no unknown
- 2019-03-07 LT LTPA2019006C patent/LTPA2019006I1/lt unknown
- 2019-03-07 LT LTPA2019005C patent/LTC2470526I2/lt unknown
- 2019-03-15 NL NL300973C patent/NL300973I2/nl unknown
- 2019-03-18 CY CY2019013C patent/CY2019013I2/el unknown
- 2019-03-18 CY CY2019014C patent/CY2019014I1/el unknown
-
2020
- 2020-01-14 US US16/741,937 patent/US20200323852A1/en not_active Abandoned
-
2021
- 2021-07-15 US US17/376,199 patent/USRE49556E1/en active Active
-
2022
- 2022-04-20 US US17/724,589 patent/US20230116233A1/en not_active Abandoned
-
2023
- 2023-01-27 EC ECSENADI20234573A patent/ECSP23004573A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202020B (en) | Compounds and compositions as protein kinase inhibitors | |
| PL2470528T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
| HUS1900014I1 (hu) | Proteinkináz inhibitorok | |
| ZA201004243B (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
| EP2200436A4 (en) | SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER | |
| IL209729A0 (en) | Novel phenylpyrazinones as kinase inhibitors | |
| HUS1500049I1 (hu) | Protein kináz inhibitor vegyületek és készítmények | |
| IL211693A0 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| PL2193133T3 (pl) | Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej | |
| IL197724A0 (en) | Compounds and compositions as protein kinase inhibitors | |
| IL198315A0 (en) | Compounds and compositions as protein kinase inhibitors | |
| EP2387572A4 (en) | PROTEIN KINASE C HEMMER AND ITS USE | |
| IL210073A0 (en) | Protein kinase inhibitors | |
| IL210069A0 (en) | Protein kinase inhibitors | |
| IL208136A0 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases | |
| HK1169107A (en) | Compounds and compositions as protein kinase inhibitors | |
| GB0807642D0 (en) | IKK- serine-threonine protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |